Citations

Showing 10 of 108083 citations.

Editorial to Special Issue “Glioblastoma: Recapitulating the Key Breakthroughs and Future Perspective”
Sharma, Amit , Guerrero‐Cazares, Hugo , Maciaczyk, Jarek , Guerrero-Cazares, Hugo

Mayo Clinic

International Journal of Molecular Sciences | January 30, 2023 | Volume: 24 | Issue: 3 | Pages: 2548

10.3390/ijms24032548 | PMID 36768870 Get It

Glioblastoma (GBM) remains the most common and aggressive malignant primary brain tumor [...]
Distinct Subtypes of Hepatorenal Syndrome and Associated Outcomes as Identified by Machine Learning Consensus Clustering
Tangpanithandee, Supawit , Krisanapan, Pajaree , Mao, Michael A. , Kaewput, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Krisanapan, Pajaree , Mao, Michael A , Kaewput, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Tangpanithandee, Supawit , Thongprayoon, Charat , Boonpheng, Boonphiphop

Mayo Clinic

Diseases | January 30, 2023 | Volume: 11 | Issue: 1 | Pages: 18

10.3390/diseases11010018 | PMID 36810532 Get It

Background: The utilization of multi-dimensional patient data to subtype hepatorenal syndrome (HRS) can individualize patient care. Machine learning (ML) consensus clustering may identify HRS subgroups with unique clinical profiles. In this study, we aim to identify clinically meaningful clusters of hospitalized patients for HRS using an unsupervised ML clustering approach. Methods: Consensus clustering analysis was performed based on patient characteristics in 5564 patients primarily admitted for HRS in the National Inpatient Sample from 2003–2014 to identify clinically distinct HRS subgroups. We applied standardized mean difference to evaluate key subgroup features, and compared in-hospital mortality between assigned clusters. Results: The algorithm revealed four best distinct HRS subgroups based on patient characteristics. Cluster 1 patients (n = 1617) were older, and more likely to have non-alcoholic fatty liver disease, cardiovascular comorbidities, hypertension, and diabetes. Cluster 2 patients (n = 1577) were younger and more likely to have hepatitis C, and less likely to have acute liver failure. Cluster 3 patients (n = 642) were younger, and more likely to have non-elective admission, acetaminophen overdose, acute liver failure, to develop in-hospital medical complications and organ system failure, and to require supporting therapies, including renal replacement therapy, and mechanical ventilation. Cluster 4 patients (n = 1728) were younger, and more likely to have alcoholic cirrhosis and to smoke. Thirty-three percent of patients died in hospital. In-hospital mortality was higher in cluster 1 (OR 1.53; 95% CI 1.31–1.79) and cluster 3 (OR 7.03; 95% CI 5.73–8.62), compared to cluster 2, while cluster 4 had comparable in-hospital mortality (OR 1.13; 95% CI 0.97–1.32). Conclusions: Consensus clustering analysis provides the pattern of clinical characteristics and clinically distinct HRS phenotypes with different outcomes.
AAPM Task Group Report 238: 3D C‐arms with volumetric imaging capability*
Supanich, Mark , Siewerdsen, J. H. , Fahrig, Rebecca , Helm, Pat, Jans, J. C., Kuhls‐Gilcrist, Andrew, Riddell, Cyril , Ritschl, Ludwig, Schäfer, Sebastian , Schueler, Beth A. , Silver, Mike, Timmer, Jan, Trousset, Yves, Schueler, Beth, Farahani, Keyvan , Gang, Grace J. , Helm, Patrick A. , Jones, A. Kyle , Koenig, Thomas W. , Lin, MingDe , Zhang, Jie

Mayo Clinic

Medical Physics | January 29, 2023 | Volume: 50 | Issue: 8 | Pages: No page available

10.1002/mp.16245 | PMID 36710257 Get It

AbstractThis report reviews the image acquisition and reconstruction characteristics of C‐arm Cone Beam Computed Tomography (C‐arm CBCT) systems and provides guidance on quality control of C‐arm systems with this volumetric imaging capability. The concepts of 3D image reconstruction, geometric calibration, image quality, and dosimetry covered in this report are also pertinent to CBCT for Image‐Guided Radiation Therapy (IGRT). However, IGRT systems introduce a number of additional considerations, such as geometric alignment of the imaging at treatment isocenter, which are beyond the scope of the charge to the task group and the report.Section 1 provides an introduction to C‐arm CBCT systems and reviews a variety of clinical applications. Section 2 briefly presents nomenclature specific or unique to these systems. A short review of C‐arm fluoroscopy quality control (QC) in relation to 3D C‐arm imaging is given in Section 3. Section 4 discusses system calibration, including geometric calibration and uniformity calibration. A review of the unique approaches and challenges to 3D reconstruction of data sets acquired by C‐arm CBCT systems is give in Section 5. Sections 6 and 7 go in greater depth to address the performance assessment of C‐arm CBCT units. First, Section 6 describes testing approaches and phantoms that may be used to evaluate image quality (spatial resolution and image noise and artifacts) and identifies several factors that affect image quality. Section 7 describes both free‐in‐air and in‐phantom approaches to evaluating radiation dose indices.The methodologies described for assessing image quality and radiation dose may be used for annual constancy assessment and comparisons among different systems to help medical physicists determine when a system is not operating as expected. Baseline measurements taken either at installation or after a full preventative maintenance service call can also provide valuable data to help determine whether the performance of the system is acceptable. Collecting image quality and radiation dose data on existing phantoms used for CT image quality and radiation dose assessment, or on newly developed phantoms, will inform the development of performance criteria and standards. Phantom images are also useful for identifying and evaluating artifacts. In particular, comparing baseline data with those from current phantom images can reveal the need for system calibration before image artifacts are detected in clinical practice. Examples of artifacts are provided in Sections 4, 5, and 6.
Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia
Heyes, Richard , Bansberg, Stephen F. , Adler, Charles H. , Zhang, Nan , Lott, David G.

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | January 29, 2023 | Volume: 9 | Issue: 2 | Pages: 168-173

10.1002/wjo2.88 | PMID 37383332 Get It

AbstractObjectivesThis study aims to analyze the impact of age and sex on botulinum neurotoxin (BoNT‐A) dosing and outcomes in adductor spasmodic dysphonia (AdSD).MethodsA database review of all spasmodic dysphonia patients treated with BoNT from 1989 to 2018 at the Mayo Clinic in Arizona was performed. Only patients who had received ≥4 injections of BoNT‐A for AdSD were included. Patients were divided into two cohorts to analyze age, with an age of first treatment cutoff of 60 years. Patients were divided into male and female cohorts to analyze sex.ResultsThe final analysis included 398 patients. The mean dose of BoNT‐A per treatment was significantly higher in the younger cohort (4.4 vs. 3.9 units, p = 0.048). The mean maximal benefit was similar (72% vs. 70%, p = 0.48); however, the mean length of benefit was significantly shorter in younger patients (3.0 vs. 3.6 months, p < 0.01). The mean BoNT‐A dose was significantly higher in the female cohort (4.2 vs. 3.6 units, p = 0.02). The mean maximal benefit was similar (69% vs. 75%, p = 0.58), as was the mean length of benefit (3.2 vs. 3.5 months, p = 0.11).ConclusionsThis study suggests that age and sex influence BoNT‐A dosing and outcomes in AdSD.
Gender differences in COVID‐19‐related manuscript authorship by hospitalists during the pandemic: A bibliometric analysis
Eliáš, Richard , Bonk, Nicole , White, Andrea T. , Payne, Shandra, Wagner, Casey, Hardin, Hannah, Kaiksow, Farah Acher , Sheehy, Ann M. , Auerbach, Andrew D. , Vaughn, Valerie M. , Elias, Richard M , Kaiksow, Farah , Auerbach, Andrew , Vaughn, Valerie M

Mayo Clinic

Journal of Hospital Medicine | January 29, 2023 | Volume: 18 | Issue: 3 | Pages: 209-216

10.1002/jhm.13045 | PMID 36709475 Get It

AbstractBackgroundHospital medicine (HM) has a well‐described gender disparity related to academic work and promotion. During the COVID‐19 pandemic, female authorship across medicine fell further behind historical averages.ObjectiveExamine how COVID‐19 affected the publication gender gap for hospitalists.Design, Settings, and ParticipantsBibliometric analysis to determine gender and specialty of US‐based physician first and last authors of COVID‐19 articles published March 1, 2020 to February 28, 2021 in the four highest impact general medical journals and two highest impact HM‐specific journals.Main Outcome and MeasuresWe characterized the percentage of all physician authors that were women, the percentage of physician authors that were hospitalists, and the percentage of HM authors that were women. We compared author gender between general medical and HM‐specific journals.ResultsDuring the study period, 853 manuscripts with US‐based first or last authors were published in eligible journals. Included manuscripts contained 1124 US‐based physician first or last author credits, of which 34.2% (384) were women and 8.8% (99) were hospitalists. Among hospitalist author credits, 43.4% (n = 43/99) were occupied by women. The relative gender equity for hospitalist authors was driven by the two HM journals where, compared to the four general medical journals, hospitalist authors (54.1% [33/61] vs. 26.3% [10/38] women, respectively, p = .002) and hospitalist last authors (51.9% [14/27] vs. 20% [4/20], p = .03) were more likely to be women.ConclusionsAcross COVID‐19‐related manuscripts, disparities by gender were driven by the high‐impact general medical journals. HM‐specific journals had more equitable inclusion of women authors, demonstrating the potential impact of proactive editorial policies on diversity.
Integrated Health Maintenance Reminders for Improved HPV Vaccine Administration: Toward Improvements in Completion Disparities
Rames, Jess D. , Frisco, Nicholas A. , Jiang, Rong , Shah, Kevin P. , Kahmke, Russel , Puscas, Liana , Rocke, Daniel J. , Osazuwa‐Peters, Nosayaba

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 29, 2023 | Volume: 169 | Issue: 1 | Pages: 76-85

10.1002/ohn.242 | PMID 36939623 Get It

AbstractObjectiveTo evaluate the effect of a health maintenance reminder (HMR) on human papillomavirus (HPV) vaccine administration and completion across different age, insurance, and race cohorts.Study DesignRetrospective pre‐post analysis.SettingAcademic primary care.MethodsPatients aged 9 to 26 who had initiated the HPV vaccine series from 2016 to 2021 were analyzed, based on current age‐based standards. The cohort was divided based on vaccine uptake before and after the implementation of the HMR program in February 2020. The multivariate analysis estimated the odds of vaccine completion based on sociodemographic factors, and variable interactions were investigated to determine independent associations between sociodemographic factors and HMR implementation.ResultsThere were 7654 individual patients (mean age was 15.8 years; 46.7 were males; and 50.7% were white). HPV vaccine completion rates increased post‐HMR implementation by 59.2% (37% pre‐, and 58.9% post‐HMR; p < .001) in the entire cohort. Overall, black patients (adjusted odds ratio [aOR] = 0.68; 95% confidence interval [CI]: 0.60, 0.70) and patients ≥18 years (aOR = 0.13; 95% CI: 0.11, 0.15) were significantly less likely to complete their vaccine series; however, this improved significantly following HMR in these groups (p < .001). Post‐HMR, race, and insurance status were not independently associated with disparate vaccine completion rates, however, age was, and patients ≤14 or younger had higher odds of vaccine completion (aOR = 3.54; 95% CI: 2.91, 4.32).ConclusionThe implementation of an HMR was associated with increased HPV vaccine uptake across age and race groups in this single‐institution study. Future research should explore barriers to implementing HMRs in different health care settings.
Relationship Between Alcohol Intolerance and Aspirin‐Exacerbated Respiratory Disease (AERD): Systematic Review
Candelo, Estephanía , McCalla, Monet, Arias‐Valderrama, Oriana , Avila‐Castano, Karol , Chelf, Cynthia , Olomu, Osarenoma , Donaldson, Angela M. , Gomez, Estephania Candelo , Chelf, Cynthia J , Donaldson, Angela M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 29, 2023 | Volume: 169 | Issue: 1 | Pages: 12-20

10.1002/ohn.248 | PMID 36939486 Get It

AbstractObjectivePrevious studies have suggested that patients with aspirin‐exacerbated respiratory disease (AERD) have a high likelihood of alcohol intolerance. The purpose of this systematic review is to identify if there is sufficient evidence to confirm this correlation and the impact of medical therapy on subsequent alcohol tolerance.Data SourcesPubMed, EMBASE, SCOPUS, EBSCO, Google Scholar, Cochrane Library, and Grey literature. We also performed snowballing on the identified observational studies (OS) for additional data.Review MethodsA systematic review was conducted from 1968 to 2022 to identify those studies describing AERD symptomatology triggered by alcohol intake. The primary outcome was to analyze the current literature for the association between alcohol intolerance and AERD symptoms. The secondary outcome looked for improvement in alcohol tolerance after aspirin desensitization or biological therapy.ResultsA total of 775 studies were identified and 40 abstracts were evaluated. From these, 5 studies met the inclusion criteria. Of the 5 manuscripts, there was 1 case‐control, 2 cohort, and 2 cross‐sectional studies. A total of 522 participants with AERD and a history of alcohol consumption were included, with 52.8% reporting at least 1 sinopulmonary exacerbation after alcohol intake. One of 3 studies noted improvement in alcohol tolerance after medical therapy with aspirin desensitization.ConclusionThe current literature suggests that patients with AERD have a high risk of alcohol intolerance. Additionally, aspirin desensitization may improve alcohol tolerance in this patient population.
Approach to Cochlear Implantation in Patients With Ventriculoperitoneal Shunts
Macielak, Robert J. , Selleck, Anne Morgan , Kocharyan, Arminé , Hunter, Jacob B. , Patro, Ankita , Hamilton, Christopher A., Patel, Neil S. , Gurgel, Richard K. , Sweeney, Alex D. , Brown, Kevin D. , Link, Michael J., Carlson, Matthew L. , Perkins, Elizabeth L , Gurgel, Richard Klaus , Hunter, Jacob B , Perkins, Elizabeth L. , Link, Michael J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 29, 2023 | Volume: 168 | Issue: 6 | Pages: 1485-1493

10.1002/ohn.220 | PMID 36939465 Get It

Abstract Objective To evaluate the safety and outcomes of cochlear implantation (CI) in patients with ventriculoperitoneal (VP) shunts to inform clinical practice. Study Design Historical cohort study. Setting Tertiary referral centers. Methods A multi‐institutional historical cohort of patients with VP shunts and CI was identified and analyzed. Results A total of 46 patients (median age 8 years [interquratile range, IQR: 2‐46]) with VP shunts and CI were identified. Of these, 41 (89%) patients had a VP shunt prior to CI. Based on institutional preference and individual patient factors, CI was performed contralateral to a pre‐existing VP shunt in 24 of these 41 cases (59%) and ipsilateral in 17 (41%). Furthermore, pre‐CI relocation of the VP shunt was performed in 3 cases (7%), and 2 patients (5%) underwent planned revision of their VP shunt concurrent with CI. In total, 2 of 27 pediatric patients (7%) required unanticipated revision shunt surgery, both contralateral to CI device placement, given VP shunt malfunction. One of 19 adult patients (5%) required shunt revision during CI due to shunt damage noted intraoperatively. Among 43 patients with available follow‐up, 38 (88%) are regular CI users, with a median consonant‐nucleus vowel‐consonant word: score of 58% (IQR: 28‐72). Conclusion CI can be performed at low risk, either contralateral or ipsilateral, to a VP shunt, and does not mandate shunt revision in most cases. Additional considerations regarding CI receiver‐stimulator placement are necessary with programmable shunts to mitigate device interaction. Preoperative planning, including coordination of care with neurosurgery, is important to achieving optimal outcomes.
Narrative review of migraine management in patients with renal or hepatic disease
Stern, Jennifer I. , Datta, Shae , Chiang, Chia‐Chun , Garza, Ivan , Robertson, Carrie E. , Robertson, Carrie E , Chiang, Chia-Chun , Vieira, Dorice L.

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 29, 2023 | Volume: 63 | Issue: 1 | Pages: 9-24

10.1111/head.14437 | PMID 36709407 Get It

Abstract Objectives/Background Treatment of migraine in the setting of either renal or hepatic disease can be daunting for clinicians. Not only does the method of metabolism have to be considered, but also the method of elimination/excretion of the parent drug and any active or toxic metabolites. Furthermore, it is difficult to think about liver or kidney disease in isolation, as liver disease can sometimes contribute to impaired renal function and renal disease can sometimes impair hepatic metabolism, through the cytochrome P450 system. Methods A detailed search for terms related to liver disease, renal disease, and migraine management was performed in PubMed, Ovid Medline, Embase, and the Cochrane Library.For each medication, product labels were retrieved and reviewed using the US FDA website, with additional review of IBM Micromedex, LiverTox, and the Renal Drug Handbook. Results This manuscript provides an overview of migraine drug metabolism and how it can be affected by liver and renal impairment. It reviews the standard terminology recommended by the US Food and Drug Administration for the different stages of hepatic and renal failure. The available evidence regarding the use of abortive and preventative medicines in the setting of organ failure is discussed in detail, including more recent therapies such as lasmiditan, gepants, and calcitonin gene‐related peptide antibodies. Conclusions For acute therapy, the use of NSAIDS should be limited, as these carry risk for both severe hepatic and renal disease. Triptans can be selectively used, often with dose guideline adjustments. Ubrogepant may be used in severe hepatic disease with dose adjustment and lasmiditan can be used in end stage renal disease. Though non‐medicine strategies may be the most reasonable initial approach, many preventative medications can be used in the setting of hepatic and renal disease, often with dose adjustment. This review provides tables of guidelines, including reduced dosing recommendations, for the use of abortive and preventative migraine medications in hepatic and renal failure.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice
Sanchorawala, Vaishali , Wechalekar, Ashutosh , Schönland, Stefan , Landau, Heather , Kwok, Fiona, Suzuki, Kenshi , Comenzo, Raymond L. , Cherepanov, Dasha , Hayden, Vanessa, Kumar, Arun , Labotka, Richard, Faller, Douglas V. , Dispenzieri, Angela , Schönland, Stefan , Sanchorawala, Vaishali , Wechalekar, Ashutosh D. , Kım, Kihyun , Dispenzieri, Angela , Merlini, Giampaolo , Kastritis, Efstathios

Mayo Clinic

American Journal of Hematology | January 28, 2023 | Volume: 98 | Issue: 5 | Pages: 720-729

10.1002/ajh.26866 | PMID 36708469 Get It

AbstractPatient‐reported outcomes in AL amyloidosis have not been well‐studied. We analyzed health‐related quality of life (HRQOL) and AL amyloidosis symptoms data from the phase 3 TOURMALINE‐AL1 trial (NCT01659658) (ixazomib‐dexamethasone, n = 85; physician's choice of chemotherapy [PC], n = 83). HRQOL and symptom burden were measured with the SF‐36v2, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale (FACT/GOG‐Ntx), and an amyloidosis symptom questionnaire (ASQ). Score changes during treatment were analyzed descriptively and using repeated‐measures linear mixed models; analyses were not adjusted for multiplicity. Least‐squares (LS) mean changes from baseline were significantly higher (better HRQOL) for ixazomib‐dexamethasone at several cycles for SF‐36v2 Role Physical and Vitality subscales (p < .05); no subscales demonstrated significant differences favoring PC. For FACT/GOG‐Ntx, small but significant differences in LS mean changes favored ixazomib‐dexamethasone over PC at multiple cycles for seven items and both summary scores; significant differences favored PC for one item (trouble hearing) at multiple cycles. ASQ total score trended downward (lower burden) in both arms; significant LS mean differences favored ixazomib‐dexamethasone over PC at some cycles (p < .05). Patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone experienced HRQOL and symptoms that were similar to or trended better than patients treated with PC despite longer duration of therapy.